We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-0.34%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
-$21.2M
Cap. Flow
+$40.7M
Cap. Flow %
1.55%
Top 10 Hldgs %
39.68%
Holding
190
New
18
Increased
27
Reduced
27
Closed
13

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$47.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$18.8M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$18M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.7M
5
PFE icon
Pfizer
PFE
+$13.7M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$47.2M
2
SYK icon
Stryker
SYK
+$24.6M
3
ZBH icon
Zimmer Biomet
ZBH
+$24M
4
HUM icon
Humana
HUM
+$20.2M
5
UNH icon
UnitedHealth
UNH
+$17.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.54%
2 Real Estate 2.01%
3 Industrials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WELL icon
101
Welltower
WELL
$167B
$2.97M 0.11%
41,484
– –
VTR icon
102
Ventas
VTR
$46.6B
$2.89M 0.11%
66,681
– –
PYXS icon
103
Pyxis Oncology
PYXS
$200M
$2.84M 0.11%
708,303
– –
LIVN icon
104
LivaNova
LIVN
$4.69B
$2.78M 0.11%
+63,880
New +$3.23M
NTRA icon
105
Natera
NTRA
$39.4B
$2.74M 0.1%
49,272
– –
BAX icon
106
Baxter International
BAX
$14.7B
$2.73M 0.1%
+67,312
New +$2.85M
RARE icon
107
Ultragenyx Pharmaceutical
RARE
$2.54B
$2.69M 0.1%
67,065
– –
ASRT
108
DELISTED
Assertio
ASRT
$2.62M 0.1%
27,372
– –
ARDX icon
109
Ardelyx
ARDX
$1.24B
$2.58M 0.1%
539,408
– –
ARWR icon
110
Arrowhead Research
ARWR
$12.6B
$2.55M 0.1%
100,422
– –
BBIO icon
111
BridgeBio Pharma
BBIO
$16.1B
$2.5M 0.1%
+150,921
New +$1.76M
CRSP icon
112
CRISPR Therapeutics
CRSP
$5.23B
$2.49M 0.09%
55,080
– –
SNDX icon
113
Syndax Pharmaceuticals
SNDX
$1.69B
$2.49M 0.09%
117,717
– –
MRTX
114
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.43M 0.09%
65,490
– –
ALGN icon
115
Align Technology
ALGN
$12.4B
$2.31M 0.09%
6,925
-43,899
-86% -$13M
GRTX
116
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$2.3M 0.09%
898,374
– –
OPCH icon
117
Option Care Health
OPCH
$3.55B
$2.06M 0.08%
64,975
– –
PHG icon
118
Philips
PHG
$25.9B
$2.02M 0.08%
128,302
– –
ICLR icon
119
Icon
ICLR
$12.1B
$1.99M 0.08%
9,334
– –
KDNY
120
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.93M 0.07%
+83,500
New +$1.99M
BCYC
121
Bicycle Therapeutics
BCYC
$275M
$1.89M 0.07%
88,676
– –
PRGO icon
122
Perrigo
PRGO
$1.49B
$1.84M 0.07%
51,224
– –
IMVT icon
123
Immunovant
IMVT
$8.08B
$1.79M 0.07%
+115,400
New +$2M
MEDP icon
124
Medpace
MEDP
$16.1B
$1.77M 0.07%
9,435
– –
TAK icon
125
Takeda Pharmaceutical
TAK
$52.9B
$1.73M 0.07%
105,073
– –
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Tekla Capital Management held 190 positions worth $2.63B, down 0.8% from $2.65B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q1 2023 filing shows 18 new, 27 increased, 27 reduced and 13 closed positions. Its largest new stake was Exelixis: 726,639 shares worth $14.1M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $47.2M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2023 buy was Exelixis: 726,639 shares worth $14.1M.
  • Tekla Capital Management added most to Elevance Health in Q1 2023, an estimated $47.3M increase.
  • Tekla Capital Management's biggest Q1 2023 reduction was Stryker, cutting an estimated $24.6M.
  • Tekla Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $47.2M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.63B portfolio in Q1 2023.
  • Tekla Capital Management opened 18 new positions and closed 13 in Q1 2023.
  • Tekla Capital Management's portfolio value fell 0.8% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q1 2023, filed 10 May 2023.